Table 3.

Linear regression for the decline in eGFR in the entire cohort according to SMg quintiles (mg/dL)

	Model 1			Model 2			Model 3			Model 4			Model 5
	β	95% CI	P value	β	95% CI	P value	β	95% CI	P value	β	95% CI	P value	β	95% CI	P value
SMg quintiles
Q1	−0.93	−1.35 to 0.50	<0.001	−0.78	−1.22 to -0.34	<0.001	−0.71	−1.15 to-0.27	0.002	−0.54	−1.08 to-0.20	0.005	−0.50	−0.95 to-0.05	0.028
Q2	−0.41	−0.82 to 0.01	0.05	−0.27	−0.70 to 0.15	0.21	−0.24	−0.57 to 0.18	0.25	−0.21	−0.54 to 0.21	0.33	−0.15	−0.58 to 0.27	0.48
Q3	−0.2S	−0.55 to 0.15	0.22	−0.18	0.50 to 0.23	0.39	− 0.18	−0.50 to 0.24	0.41	−0.15	−0.55 to 0.27	0.48	−0.12	−0.53 to 0.30	0.58
Q4	−0.27	−0.59 to 0.14	0.2	−0.20	−0.52 to 0.23	0.35	− 0.20	−0.53 to 0.22	0.35	−0.17	−0.59 to 0.25	0.44	−0.12	−0.54 to 0.30	0.58
Q5	Ref.	–	–	Ref.	–	–	Ref.	–	–	Ref.	–	–	Ref.	–	–

Model 1 was adjusted for age, gender, race/ethnicity, body mass index at DHS-1.

Model 2 was adjusted for variables in model 1 plus serum phosphorus, calcium, bicarbonate, albumin, Intact parathyroid hormone, total cholesterol and high-density lipoprotein at DHS-1.

Model 3 was adjusted for variables in model 2 plus use of diuretics, dietary supplements. ACEI and ARB at DHS-1.

Model 4 was adjusted for variables in model 3 plus prevalent hypertension and CRP at DHS-1.

Model 5 was adjusted for variables in model 4 plus prevalent type 2 diabetes at DHS-1.

β, change in eGFR In reference to the highest quintile of SMg levels. eGFR was calculated according to the MDRD study equation. ΔeGFR was calculated as eGFR at D HS-2 minus eGFR at DHS-1.

ACEI, ACE Inhibitors; ARB, angiotensin II receptor blockers; CRP, C reactive protein; DHS, Dallas Heart Study; eGFR, estimated glomerular filtration rate; SMg, serum magnesium.